Progress in Stem Cell Therapy for Male Pattern Hair Loss: How Wnt Pathway, Growth Factors, and Stem Cell Signals Affect Cell Growth and Hair Follicle Development

Hair tissue engineering and stem cell therapy are new approaches to treating hair loss (HL). Methods using exogenous cell sources or progenitor cells (PCs) are being tested in cell treatment clinical trials. These trials incorporate cells obtained from allogeneic and autologous sources. Specifically, intra-surgical cell treatments that incorporate autologous cell-based treatments with a one-step approach (cell harvesting, minimal manipulation, and immediate injection) into a single technique offer tremendous potential; a few methodologies have achieved clinical application. The intra-surgical cell treatment process involves tissue collection and preparation to obtain the desired cell product, followed by careful evaluation using the clinical application, and then cell conveyance. Intra-surgical cell treatment benefits from the availability and safety of using the patient’s own cells, which do not trigger an adverse reaction, as well as from the numerous important cell types that can be harvested using minimally invasive strategies [1].

This treatment bypasses a significant number of restrictions associated with exogenous cell treatment by avoiding in vitro cell control and expensive cell extension, the requirement for good manufacturing practice (GMP) facilities, the need to procure a work force for cell culture preparation, the potential for pollution, and a second method (at an alternate time point) to collect the cells. It might be helpful to maintain a strategic distance from the cell culture to restrict phenotype changes that may occur when cells are expelled from their local microenvironment for an all-encompassing time period [1].

Additionally, the techniques are entirely performed inside the surgical room (in absence of culture growth), which may lessen the hold-up time for the medical procedure. The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other administrative specialists consider grown-up cell products as biological products that can be partitioned into two classes: minimally manipulated biological products (obtained through centrifugation, filtration, and isolation without cell expansion) and manipulated biological products (obtained through culture-expanded stem cells). Certain intraoperative cell approaches fit the minimally-manipulated biological product category in which broad clinical trials are not required, consequently speeding up potential interpretation to facilities.

HL is determined by an assortment of factors: inherited (trichodystrophy and androgenetic alopecia), accompanying comorbidity conditions, hormonal clutters (thyroid organ disease, insulin resistance), immune system (patchy alopecia and lupus erythematous), nutritional scatters, environmental elements (drugs, ultraviolet (UV) radiation), mental disorders (stress and trichotillomania), and aging. Harming factors influence the hair cycle (HC) and reduce stem cell activity and hair follicle recovery capacity [2].

A clinical need exists for the advancement of biotechnology to enhance hair growth to address the HL issue, specifically, in cases of androgenic alopecia (AGA).

AGA is a dynamic and incessant HL issue affecting 80% of white males and 40% of white females below the age of 70, in which lymphocytes and mast cells have been identified around the miniaturizing follicle in the stem-cell-rich knot zone [3,4,5,6]. The scaling down of the follicles (i.e., miniaturization) is characterized by a depletion of the anagen stage, with an enhancement in the measure of resting hair follicles (HF), telogen, and the presence of infinitesimal hairs on a bald scalp [5,6,7].

Current drugs available to treat AGA include medications such as Finasteride^®; topical moisturizers such as Minoxidil^®, and surgical procedures such as hair transplantation [4]. In HL scalps, the hair follicle stem cell numbers remain unaltered; however, the quantity of the more effectively multiplying PCs significantly decreases [7].

Along these lines, the aim of hair tissue engineering is developing new autologous advancements to induce hair regrowth by in vitro and ex vivo cultures or by in vivo recovery and bio-stimulation. Autologous stem cells (SCs) have been of particular interest for application in hair regrowth. Some early endeavors in the field concentrated on disengaging essential cells from a biopsy of the scalp tissue and maturing the cells ex vivo for a resulting injection into the patient.

Alopecia includes modifications to two sorts of hair SCs, represented by the hair follicle stem cells (HFSCs) and the dermal papilla cells (DPCs) [8,9].

HFSCs and DPCs guarantee conditions for appropriate hair recovery and regeneration [9]. In scarring alopecia (lupus erythematous, lichen planus), provocative cell invasion around the bulge results in an irreversible loss of HFSCs. Despite the PCs being harmed, HFSCs are saved in patchy and AGA, and this is the reason why this kind of HL can be reversible [9].

Bulge SCs have been progressively portrayed, particularly in murine HFs, thereby promoting their recognition, although no widespread marker has been found for them. An example is cytokeratin 15 (CK15), which explains why CK15+/integrin α6+ or CD34+/integrin α6+ cells have been distinguished as bulge cells [10].

Research on murine HFs has shown the expression of CK19 [11,12] and various transcriptional factors, that is, Gli1, Sox9, LHX2, Hopx, Tcf3, and Nfatc1, [11,13]. The expression of specific markers relies on the HC stage and on the exact area of the cells inside the bulge [11,14]. Lgr5, a receptor engaged in the Wnt signaling pathway, has been distinguished as a genuine marker of HFSCs [13].

The SCs of the upper and lower parts of the bulge in telogen HFs influence the expression of CD34 and part of the lower portion of Lgr5. Cells that are involved in the growth of another anagen hair express Lgr5 and not CD34 [15].

Cells of the upper piece of the bulge present a higher expression of Nfatc1, which is related to a condition of rest [6]. Expression of Lgr6 [14,16] and Lrig1 [14,17] has been observed inside the isthmus. The PCs of the germinal matrix are obtained from the SCs of the bulge, but unlike them, the PCs display a high grade of P-cadherin [11,18].

Human HFSCs (H-HFSCs) are less known than murine HFSCs (M-HFSCs). It appears that specific markers are normal in both human and mouse HFSCs: CD34 [19,20], K15 [8,19], K19 [19,21], and CD200 [8,19,20]. The presence of different markers (i.e., Sox9 and LHX2) requires further examination [22]. Markers found only in H-HFSCs are PHLDA1 [19,23] and EpCAM/Ber-EP4, which is considered a valuable marker of the telogen optional hair germ [18,19]. Dermal papilla (DP) cells present distinctive markers, including the cells from hair follicle cells (HFs) and dermal fibroblasts [24]. Alkaline phosphatase (ALP) is critical for both human and murine HFs, and it is the most explicit of the markers [21,22,24]; wherein its high action is considered a marker of DP cell separation [24,25]. Additionally, α-SMA [24,25], laminin, ad fibronectin [24], and CD133 [24,26] expression have been observed in DPCs.

Marker expression modify in disease states. The immunoreactivity of CK15 is diminished in individuals with patchy alopecia, and is also identified in AGA [10]. HF of the scalp’s front part displays a shortage of CD34 in AGA, whereas its appearance is conserved in HF of the occipital locale [10]. In patchy alopecia, CD200, another marker of matrix cells, is expressed ineffectively, which might be an indication of a reduction in the immune benefit contributing to pathogenesis (i.e., response of auto reactive lymphocytes) [10,27].

SCs in the bulge remain in the resting stage for the vast majority of their lives, yet they can be actuated by relying upon the HC stage. Several theories with respect to the course and control of the HC have been proposed amid research in mouse models [12]. From the HC in mice, in the anagen stage, SCs in the bulge are separated multiple times and remain inside the niche, whereas cells of the germinal matrix divide strongly and produce the maturing hair shaft. During the catagen stage, cells from the germinal matrix experience apoptosis, while SCs of the bulge move out of it to the outer HF and, in this manner, toward the finish of the catagen stage, where they shape another bulge around the hair stem and another germinal matrix under the bulge. SCs in the bulge remain in a condition of rest during the telogen stage, and between the telogen and anagen stages, where they self-recover or move, creating a pool of germinal framework cells that multiply to shape the hair matrix [28].

The priority is on derivative cells in the bulge, which are the alleged SCs progenitor cells of the germinal matrix in the outflow of genes that influence stem cell activation, which have priority in expansion during the recovery cycle, even before the cells in the bulge [11,29,30].

The interpretation of the HC into the human HC has a few constraints due to the distinctive lengths of anagen [31,32], asynchrony of the human cycle [31,33], or the alternate response to the impact of hormonal variables [31,34]. Different papers reported the results of human scalp skin xenografted onto immune-compromised mice to set up the HC course in vivo in people [31,35].

The action of SCs in the bulge is controlled by its microenvironment (i.e., a supposed niche). This microenvironment incorporates the daughter cells of the SCs in the bulge, which enact their self-recovery ahead of schedule and in the late anagen stages [36]. SCs are fundamentally influenced by the mesenchymal cells (MCs) of the DP, which are in close contact with the cells of the germinal matrix that are isolated by the basal membrane [14]. They appear to be of vital significance in the activation of hair growth and in signal transmission during recovery [11,30].

Investigations have demonstrated that hair recovery is impossible after laser treatment, on the grounds that the HF cycle stops at the telogen stage without advancing to the anagen stage [14,28,30,37]. Infusions of exosomes obtained from DPCs to HFs have been found to accelerate the passage of anagen and catagen delay by means of the β-catenin and Shh pathways [38]. HFSCs are additionally influenced by fibroblasts in the reticular and papillary layers of the dermis, in addition to the subcutaneous tissue [14]. Inside the niche, there are melanocyte SCs that are in charge of the formation of mature melanocytes that confer color to maturing hair. The survival and growth of MSCs relies on signs transmitted by the HF epithelial cells (ECs), for instance, the TGF-β or the Wnt pathway [14,36]. The extracellular matrix is another part of the microenvironment. It specifically influences the SCs through the arrangement of the basal layer, in which undifferentiated cells are in contact and regulated, for instance, by integrins [11,28].

HFs are immunologically-favored spots, similar to the cerebrum, eyes, and gonads, and they are influenced by the neuroendocrine-immune system [26]. In physiological conditions, this is influenced by: (1) Low expression or non-appearance of the principle MHC I antigens, (2) the presence of malfunctioning Langerhans cells, and (3) local expression of immunosuppressive substances (TGF-β1 and α-melanocytes MSH) [26,39]. Inferred from this is that HFs can be effortlessly used in transplantation.

Multipotent SCs can re-generate HFs with sebaceous organs in the skin. Given current information, SCs can be used to regenerate hairs in a few therapeutic methodologies such as: (1) Reversing the pathological mechanisms that determine HL (particularly in AGA), (2) regenerating mature HFs from their parts (cells in the bulge can regenerate an entire hair), and (3) neogenesis of HFs from a SC-culture with separated cells or tissue designing [40,41,42].

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consider grown-up cell products as biological products that are isolated into two classes: minimally manipulated biological products and manipulated biological products. Regulation number 1394/2007 of the European Parliament for cutting-edge treatments defines “bioprocess engineering products,” which excludes products that contain or are made solely of cells and non-vital human or animal tissues that do not have pharmacological, immunologic, or metabolic activity. Included amongst the advanced therapy pharmaceutical products are ones used for gene and somatic cell treatment (Directive 2001/83/European Parliament, Annex I). Cells and tissues are to be viewed as results of the bioprocess engineering products in the event that they experience “extensive manipulation”. This rule contrasts between extensive and minimal manipulation. Manipulations that are not considered as bioprocess engineering include the following: cutting, granulating, forming, purification, centrifugation, absorbing anti-toxins or antimicrobial arrangements, cleansing, lighting, partition, fixation or decontamination, filtration, lyophilization, solidifying cryopreservation, and nitrification. The definition of medicines for advanced therapy excludes non-repetitive preparations completed under the supervision of a doctor running an individual remedy for a product explicitly intended for that specific patient, without obviously disregarding the important standards that identify with quality and security.

Further to the execution of Article 17 of Regulation (EC) No 1394/2007 (the Advanced Therapy Medicinal Products (ATMPs) Regulation), applicants are required to approach the Committee for Advanced Therapies (CAT) with a logical proposal for the arrangement of ATMPs. The committee is in charge of surveying the quality, well-being, and viability of cutting-edge treatment medications, including medications delegated as quality treatment, substantial cell treatment, or tissue-built products. CAT is supported by the ATMP regulation, which empowers the EMA in a joint effort with the European Commission to decide if a given product meets the logical criteria that characterize ATMPs. The ATMP grouping technique was introduced with the goal of addressing inquiries into situations where the arrangement of a product dependent on genes, cells, or tissues is not clear. The CAT issues logical proposals to determine if the product falls within the definition of an ATMP in the European Union. The ATMP Regulation and Directive 2001/83/EC Annex I Part IV [30] provide exact legal definitions of ATMPs.

The ATMP characterization depends on an assessment of whether a given product satisfies one of the characteristics of gene therapy medicinal products (GTMP), somatic cell therapy medicinal products (sCTMPs), or tissue engineered products (TEPs), and whether that product satisfies the definition of a consolidated ATMP. It is additionally recognized that, because of the complex nature of these restorative products, the constrained information bundle at the beginning period of the product improvement, as well as the rapid growth of science and innovation, may result in inquiries off the fringe.

Adult stem cells and PCs can be intra-surgically collected from a few tissues, including fat tissue, scalp tissue, bone marrow (BM), and peripheral blood. Previously, BM was viewed as a widely recognized source for these cells, since it was effortlessly and quickly obtained and because several devices were available for gathering BM. BM contains hematopoietic cells and MCs, as well as different cells types that may be involved in advancing tissue regeneration and hair regrowth. One of the primary constraints of intra-surgical SCs treatment approaches was the restricted amount of reaped source material and the low yield of cell detachment conventions, which yielded SCs at a frequency per mono-nucleated cell of one in every 10,000 cells to one in every 100,000 cells [43,44,45,46]. To overcome these difficulties and to avoid the highly invasive procedure of BM harvesting that causes pain at the donor area, additional elective sources from which to separate autologous SCs ought to be considered.

Fat tissue is an interesting source of cells that have multi-lineage separation potential. This tissue tends to be harvested using a less invasive technique, represented by liposuction and in larger amounts than in BM [47]. In fact, fat tissue harvest is much easier and less painful for the patient compared with BM gathering, in which it is necessary to use a trocar to drill the iliac crest [47]. A few investigations have reported different examinations and analyses between SCs obtained from various sources [47,48,49,50]. Peng et al. [47] included an immunophenotypic investigation of SCs separated from rodent BM and fat tissue, and uncovered a noteworthy level of CD44+, CD73+, and CD90+ cells in fat tissue. Increased multiplication potential in cells detached from fat tissue was proposed, citing a higher and steadier growth rate all through 10 generations, a lower populace-doubling time, the highest proportion of cell populace in the S stage, and higher telomerase activity. These outcomes were confirmed by other examinations that emphasized the evaluation of various grownup, undifferentiated cell sources [48,50]. Fat tissue must be viewed as a real alternative to BM for intra-surgical use based on SCs wealth and expansion potential. A few patients may have constrained or minimal fat tissue for autologous settings, given the high frequency of adipose tissue-derived MSCs (their occurrence is 100 to 300 times higher than in bone marrow, and the number of SCs that can be counted per unit volume of fat harvested is approximately 10-fold greater than that from BM), small fat tissue repositories may still be adequate for SCs separation [48,51,52,53]. When gathering fat tissue for intraoperative SCs treatment, the tissue reaping site and the surgery affect the yield of undifferentiated cells. For example, fat tissue harvested from the abdominal region through resection or liposuction yields more SCs in contrast with ultrasound-assisted liposuction and with the fat tissue collected from the hip/thigh district [52].

For scalp tissue, in the preliminary examination performed by Cole J.P. et al. [53], they developed another system to separate human adult SCs with minimal manipulation depending on the centrifugation of fragments of human HFs without extension or culture. Specifically, the authors reported, for the first time, the results obtained in a hair regrowth study using a therapeutic device called Rigeneracons^® (CE confirmed Class I, Human Brain Wave, Turin, Italy) that was used to obtain autologous micrografts containing HF-MSCs from centrifugation of a punch biopsy of the scalp, easily accessible for use in patients affected by AGA. The micrograft units were obtained by the disaggregation of a 2 mm punch biopsy by selection of a cell populace with a diameter of 50 microns. High cell viability was reported [53]. Noteworthy limitations include the challenge in growing cells to adequate numbers for human use, the need to conduct this expansion in good manufacturing practices (GMP) research centers, and the viability of the extended cells [54].

Therefore, the clinical use of HF-MSCs to enhance hair regrowth has not been satisfactorily considered. In other works [40,53], authors cited the amount of CD44+ cells (hair follicle-determined mesenchymal SCs) from the DP, and the level of CD200+ cells (hair follicle epithelial-SCs) from the bulge, obtained by means of the customized centrifugation of 11 punch tests [40,53]. The authors reported the microscopic evaluation of punch biopsy samples, performed using cytospin, immunocytochemistry, and the histological examination achieved by hematoxylin and eosin staining and clinical appraisal, where they discussed improvements to the current systems available for the recovery and regeneration of hair follicles. The authors emphasized permitting neo-genesis of HFs in adult individuals using isolated cells and biotechnologies [53].

The use of growth factors in autologous platelets was determined to provide substantial help in hair tissue regeneration owing to the platelets’ ability to advance neo-angiogenesis, cell expansion, and separation [55,56,57]. Platelet-rich plasma (PRP) contains no less than six fundamental growth factors, including the fibroblast growth factor (b-FGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), transforming growth factor-β (TGF-β), and insulin-like growth factor-1 (IGF-1) discharged after platelet actuation [58]. Every one of these significant growth factors is engaged in an explicit bio-molecular activity.

Another field involves the possibility of using fat and stromal vascular fraction cells (SVFs) for hair regrowth. SVFs are a heterogeneous gathering of non-cultured cells that can be constantly isolated from fat using minimal manipulation, using centrifugation, filtration, and the purification of fat tissue (proposed by EMA-CAT), or using enzymatic digestion (not proposed in the EMA-CAT suggestions). These cells work through paracrine frameworks to improve adipocyte suitability. Festa et al. [59] reported that adipocyte ancestry cells support stem cell function and help to drive the hair growth cycle. This follicular regenerative methodology is incipient and raises the probability that the HC in male and female HL can be driven or restored using autologous fat enhanced with SVF. Perez-Meza et al. [60] reported the safety and tolerability of these fat graft procedures in patients affected by inherited alopecia treated with sub-cutaneous scalp injections of fat tissue. An augmentation of 31.0 hairs/cm² was recorded in patients receiving a treatment of fat enriched with SVFs, where one subject who received fat alone (without SVFs addition) revealed a mean improvement of 14.0 hairs/cm², suggesting that fat grafts could be a treatment method for early HL, where the fat enhanced with SVFs may improve this response [60]. These studies suggest that scalp SVF-enhanced fat grafts could be a promising elective approach to treating HL in individuals. Fukuoka et al. [61] investigated the effects of fat-derived stem cell-conditioned medium injection in a gathering of 22 patients affected by AGA. Patients received treatment every three to five weeks for a total of six sessions. The mean augmentation in the hair number (hairs/0.65 cm²) was 29 ± 4.1 in men and 15.6 ± 4.2 in women. No significative difference was observed between men and women.

An examination of the studies suggests that HF neo-genesis using human ECs and dermal cells is an extremely cumbersome process that requires novel culture conditions, somehow replicating the conventional or embryonic skin conditions and the use of embryonic or neonatal cells. There are no tissue regeneration protocols used in hair transplants involving the use of AD-SVFs. Zanzoterra et al. [62] analyzed the capacities of cell solution in the Rigenera^® (Human Brain Wave, Turin, Italy) framework, which was obtained by the mechanical fracture of subcutaneous and fat tissue from the occipital region. The cell solution was injected into the hair transplant region, thereby expanding the measure of growth factors. Microscopic damage was seen to resolve more rapidly and the transplanted hair matured constantly, even two months after the strategy, wherein the telogen stage was abbreviated [62].

AD-SVFs-conditioned medium (AD-SVFs-CM) was used for patients with HL in an examination by Fukuoka and Suga [63]. A commercial product containing a protein arrangement with AD-SVFs was used (AAPE, Prostemics, Seoul, Korea), which had different growth factors (HGF, FGF-I, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage-colony-stimulating factor (GM-CSF), IL-6, VEGF, and TGF). The treatment (0.02 mL/cm² of the arrangement) was performed by injecting the suspension intradermal every three to five weeks (for four to six sessions), and hair growth was checked using trichograms. A real enhancement in hair thickness was accomplished in patients of both sexes [63]. Shin et al. [64] used AD-SVFs and the conditioned media of AD-SVFs (AD-SVFs-CM) in an observational examination of 27 women with female pattern hair loss (FPHL). The use of AD-SVFs-CM demonstrated efficacy in treating FPHL following 12 weeks of treatment, citing improvements in hair thickness and hair density without serious side effects [64]. Won et al. [65] also demonstrated that the use of AD-SVFs-CM upgraded the multiplication of cultured human DPCs by up to 130% [65].

Different examinations confirmed that enhancing fat tissue with SVFs supports adipocyte viability and yields better outcomes in a hair transplant treatment when they are applied in grafts [66,67].

Many papers on PRP have been published, yet the outcomes are frequently conflicting. The authors take the perspective of not discussing PRP in general, though it is advisable to distinguish the different types of PRP relying on their cells content and fibrin design. Therefore, it is conceivable to recognize:

As discussed, there are too many protocols for the preparation of PRP depending on the different times for centrifugation and RPM used, the number of platelets, the accessibility of growth factors, and chemokines. Additionally, wide biological (among patients) and temporal (day-by-day) variation have been reported in the methods [88]. Thus, it is hard to evaluate which kind of PRP planning is better for clinical indications [89].

Diverse PRP products may be adequate for treating distinctive kinds of balding. The clinical efficacy of PRP is still under discussion, and a standardized protocol has not yet been created [90]. Doctors should choose the appropriate PRP preparations given their bio-molecular characteristics and clinical indications [91].

As of late, the use of low-level laser treatment (LLLT) has been proposed as a treatment for AGA and enhancing hair regrowth. The authors proposed LLLT 15 days after each treatment to stimulate hair regrowth during the HF-MSCs and PRP treatment, and every three weeks after the last treatment for a period of six months. Regarding this field, 11 papers were reviewed by Afifi et al. [92], where nine papers assessing hair count/hair density found noteworthy improvements in the men and women following LLLT treatment. Hair thickness and rigidity were found to be improved in two papers. Patient satisfaction was also accounted for in five of the works.

Autologous platelet-rich plasma (A-PRP) is now connected with enhanced surgical results and lower repeat rates when used in the gingival retreat and keloid treatments, respectively [93,94]. In dermatological uses, differences were discovered when PRP treatments were performed with the activated autologous PRP (AA-PRP) instead of the non-activated A-PRP. At the point when A-PRP is used with autologous thrombin to yield AA-PRP, healing of bone exposure [95], chronic injuries as severe hidradenitis suppurativa [96] and shorter recuperation times were observed for profound burns [97,98]. Similarly, laser use for acne produces subjectively better outcomes with fewer reactions when performed in combination with either topical or intradermal use of calcium-activated PRP [99]. These outcomes might be ascribed to the discharge and concentrations of alpha-granule proteins, including growth factors and cytokines, that stimulate cell separation and proliferation, angiogenesis, and vascular modeling [100].

In the treatment of HL, the topical use of AA-PRP with the collected follicles preceding implantation has been shown to build their survival rate by 15% [101]. Patients treated with calcium gluconate-initiated PRP displayed expanded hair thickness three months post-medical procedure, with terminal hair thickness (measurement > 40 μm) increasing by 19% during that time [102]. These discoveries were affirmed in an examination of AGA patients treated with calcium-activated PRP over a span of one year [103]. After 12 weeks from the last infusion of PRP, hair thickness reached a 19% expansion over the baseline estimations. At the one-year point, hair thickness decreased to 7% above the standard estimation, although this was still established as a significant increase in hair thickness in contrast to the baseline esteems [103].

The growth factors (GFs) acquired by the degranulation of the alpha-granules appear to stimulate hair regrowth. In detail, IGF-1 stimulates the multiplication of cycling Ki67+ basal keratinocytes [104,105], whereas TGF-β1 secures the proliferative capability of basal keratinocytes by repressing cell growth and terminal separation [106,107]. PDGF-AA increases the hair inductive action of DPCs when used in combination with fibroblast growth factor 2 (FGF-2) [108,109]. VEGF stimulates angiogenesis, and PDGF-BB is a strong chemo-attractant for wound macrophages and fibroblasts by stimulating these cells to discharge endogenous growth factors, including TGF-β1, which advances new collagen synthesis [110].

DPCs harvested from the human scalp have shown improved proliferation, improved Bcl-2 and FGF-7 levels, activated ERK and Akt proteins, and up-regulation of β-catenin when cultured in an initiated PRP-enhanced growth medium [111]. Each of these elements decidedly impacts hair growth through cell multiplication to prolong the anagen stage (FGF-7) [29], stimulating cell growth (ERK enactment) [112], invigorating HF development (β-catenin) [113], and stifling apoptotic signals (Bcl-2 discharge and Akt actuation) [114,115]. The human scalp affected by AGA treated with PRP injections should show significant increases in cell activity. Histological examinations of A-PRP- and AA-PRP-treated scalps from our past work [116] provide such clinical proof. In both patient populaces, the authors observed an enhancement in the number of follicular bulge cells and follicles, epidermal thickening, enhanced vascularization, and a higher number of Ki67+ basal keratinocytes in the PRP-treated scalp tissue compared to the placebo.

Hair regrowth in a clinical evaluation demonstrated a positive reaction to treatment with A-PRP in patients showing significative improvements in hair density and hair count in the treated zone over the control zone (treated with the placebo). Differences between the 12-week follow-up hair counts and the baseline hair counts were observed. These hair growth parameters were higher in the A-PRP treatment group than in the AA-PRP treatment populace, as reported in past preliminary data reported by Gentile et al. [116]. Specifically, three-month hair density estimations for patients treated with A-PRP and AA-PRP were 65 ± 5 and 28 ± 4 hairs/cm², respectively. The outcomes established a 31 ± 2% improvement in hair density when the A-PRP treatment was performed versus a 19 ± 3% improvement in hair density when the AA-PRP treatment was performed, with a significant difference in hair growth (p = 0.0029). The increase in the hair growth parameters for A-PRP over AA-PRP may mirror the proficiency of in vivo thrombin in activating platelets and the body to distribute the contents of the activated platelets compared to in vitro calcium activation and infusion. The delivery of A-PRP may empower the production of thromboxane A2 (TXA2) by the platelets once they are activated in vivo, which would activate additional platelets and amplify platelet aggregation [117].

It is hard to find particular strategies to enhance the regeneration of HF under conditions suitable for an adult individual. Given the knowledge on ECs and dermal cells, and their relationship in the midst of embryonic hair age and adult hair cycling, various scientists have tried to obtain mature hair follicles using techniques and procedures that rely on the causes for AGA [42,118]. In a preliminary examination [53], the authors developed another procedure to separate HFSCs using minimal manipulation, depending on the centrifugation of pieces of human hair follicles without cell expansion or enzymatic digestion. They reported the tallying of these cells and the preliminary results obtained from injections of micrografts containing HFSCs in the scalps of patients affected by AGA showed improvements in hair density. Gentile et al. [53] reported the amount of CD44+ cells from DP and the level of CD200+ cells from the bulge obtained using the customized centrifugation of 11 punch tests [53]. They also reported the microscopic evaluation of punch biopsy samples, determined by cytospin and immunocytochemistry, histological examination using hematoxylin and eosin staining, and clinical appraisal. The authors now seek to discuss improvements to the current systems available for the recovery and regeneration of hair follicles, focusing on systems permitting neo-genesis of hair follicles in adult individuals by using isolated cells and biotechnologies [53].

Examinations were performed using rodent cells, particularly of embryonic or infant origin. No fruitful procedure to produce human hair follicles from adult cells has been found. Possibly, the most crucial point is creating 3D culture conditions reflecting the structure of living tissue. It is necessary to improve the culture conditions that allow the expansion of specific cells while preserving their inductive properties, as well as procedures for picking masses of epithelial stem cells (ESCs), which should provide the principal instruments to overcome the difficulties constraining human HF neo-genesis [42]. These cells give the impression of being arranged in the bulge district of human hair follicles.

What are the advantages of using SCs from Wharton’s jelly compared to other MCs? Wharton’s jelly is a particular source of SCs due to its accessibility, vast pool of donors, non-invasive and easy harvesting, no hazard to the donor, no moral impediments, limited immunogenic potential, and high multi-potential separation ability [137,138]. In addition, the exposure to infectious agents seldom happens, which ensures security to the contributor [139]. The decellularized Wharton’s jam matrix (DWJM) (fresh jelly exposed to two cycles of osmotic shock, alternately with a hypertonic suspension of NaCl, mannitol, MgCl₂, and KCl with an osmolarity of approx. 1.275 mOsm/L, centrifuged at 5000 rpm at 4 °C with a hypotonic arrangement of 0.005% Triton X-100) can provide a characteristic scaffold to SCs as a biocompatible matrix, which bolsters their viability, triggering conglomeration of MCs. DWJM contains TGF-β, collagen I, fibronectin, and tenascin, which might be in charge of condensing the added WJMSC in a few regions of the DWJM. In synthesis, DWJM is a natural biocompatible 3D matrix that guarantees adhesion, penetration, growth, and multiplication of cells, both in vitro and in vivo. To summarize, the report presented DWJM as a normal 3D scaffold that can be used in tissue designing and as a regenerative drug [140].

Maintaining a pool of SCs is vital for tissue homeostasis and harm fix. Their divisions are not frequent in mature organisms, and their greater part are in a lethargic state. As such, it is vital to comprehend the components of their activation and induction, which will allow for the use of multi-potent cells in regenerative plastic surgery and hair regrowth. Their use is complicated by the fact that the expression of receptors on the various growth factors and the effect of the microenvironment may vary.

Not all target points in SC therapy have been distinguished. The information provided in this review features the useful impacts of AD-SVFs and PRP on hair regrowth, notwithstanding the preliminary positive outcomes from HF-MSCs. The activation and increase of Wnt signaling in DPCs is the crucial factor that enhances renewed hair growth.

The current knowledge in biology, the limits of past translational research that included development of pre-clinical and clinical models, harnessing of new strategies for more accurate imaging, and biomarker-based diagnostics will provide a strong basis to advance viable clinical approaches for regenerative aims in hair tissue engineering. Moreover, larger, randomized, double-blinded, controlled trials are needed to optimize cell administration protocols and to confirm the early observations of promising clinical outcomes.

Conceptualization, P.G. and S.G; methodology, P.G.; validation, P.G. and S.G; formal analysis, P.G.; investigation, P.G.; resources, P.G. and S.G.; data curation, P.G and S.G.; writing—original draft preparation, P.G.; writing—review and editing, P.G.; visualization, P.G.; supervision, P.G and S.G.; project administration, S.G.; funding acquisition, P.G. and S.G.

This article received no external funding.

The authors declare no conflicts of interest.